Media Coverage
January 12, 2023
Our CEO, Jose Mejia Oneto and Nobel Laureate Carolyn Bertozzi talked about Shasqi being the first with click chemistry in the clinic
December 02, 2022
Ron Leuty from the San Francisco Business Times met with Nobel Prize winners Carolyn Bertozzi and Jennifer Doudna to talk about the future of click chemistry and CRISPR. They discussed how Dr. Bertozzi has been a Shasqi supporter from the beginning.
November 02, 2022
Brian Buntz wrote a great article about Shasqi and how we've been working on click chemistry in humans
October 27, 2022
Our CEO, Jose, sat down with Karissa Waddick from PharmaVoice to talk about how Shasqi is pioneering Nobel prize winninng technology click chemistry in humans and what we believe the future holds.
October 5, 2022
Shasqi advisor Carolyn R. Bertozzi has been awarded the Nobel prize for her work on click chemistry and bioorthogonal reactions.
September 26, 2022
Cancer is a leading cause of death worldwide, accounting for nearly one in six deaths in 2020. We connected with Endpoints News on unlocking the hidden potential of click chemistry to improve the therapeutic index of cancer therapies.
May 31, 2022
Chemistry World dives into the world of bioorthogonal chemistry and how this amazing technology is now being leveraged in click chemistry by Shasqi and other companies.
March 21, 2022
Could the first 'click chemistry' treatment for cancer patients, which is already in Phase 1 clinical trials, reduce the side effects associated with chemotherapy?
March 3, 2022
Stanford magazine interviewed Shasqi advisor Carolyn Bertozzi about her years of experience and bioorthogonal chemistry which is used in our technology
January 5, 2022
A major challenge in the development of novel therapeutics is the precise localization and activation of drugs to specific areas in the body. We shared our thoughts with STAT News on how click chemistry could contribute to solving this challenge.
November 16, 2021
Jose and Sebastian have been working on Shasqi almost from the start, but what most don't know is that they were room mates at Macalester College
November 12, 2021
We met on Zoom with Ron Leuty of the San Francisco Business Times, who covered Shasqi a few times before, to catch up on our Series B funding.
November 11, 2021
Fierce Biotech's, Emmy Lucas covers Shasqi's announcement of having raised a $50 million Series B.
November 11, 2021
We are excited to have been featured in Endpoints News, discussing our recent fundraising news of Series B and what we hope to achieve with the use of funds in the next year.
November 10, 2021
Bioworld, in a brief summary, highlighted the updated interim data from Shasqi's ongoing SQ3370 clinical study.
October 28, 2020
Derek Lowe shared a great summary about our R&D path of our click chemistry oncology platform, leading to a first-in-human clinical trial.
October 23, 2020
A therapy that relies on click chemistry to target a powerful cancer drug at tumor cells, sparing healthy ones, has entered Phase 1 clinical trials. It marks the first time that a click chemistry reaction has been carried out inside a patient’s body, according to Shasqi, the San Francisco–based biotech firm that developed the therapy.
October 14, 2020
Katie Jennings wrote an amazing article about Shasqi’s milestone moving into the clinic with our first patients in the last quarter.
January 07, 2020
We are proud to share an article by Ron Leuty, Staff Reporter for the San Francisco Business Times about Shasqi and our attendance at the JPMorgan 2020 conference: “How a small biotech worked its way out of storage space during the industry's biggest conference”
July 5, 2019
Mark Peplow writes about Click Chemistry across several companies around the world. "Bioorthogonal chemistry, already a workhorse of drug discovery research, prepares for the leap into human testing."
June 08, 2017
We’re excited that our founder, José M. Mejia Oneto has featured on a list of seven promising researchers in the biotech world. The article was published by Lauren Hepler in the San Francisco Business Times “These seven researchers are changing the face of biotech”
Press Releases
February 23, 2023
Shasqi announces the appointment of industry veteran Jean-Frédéric Viret, PhD as Chief Financial Officer to drive financial strategy for Shasqi platform expansion.
October 6, 2022
Shasqi announced today that The Nobel Prize for Chemistry has been awarded to the company’s scientific advisor, Carolyn Bertozzi, Ph.D., alongside Morten Meldal, Ph.D. (University of Copenhagen, Denmark), and Nobel Laureate K. Barry Sharpless, Ph.D. (Scripps Research, La Jolla, CA, USA), for the development of click chemistry and bioorthogonal chemistry.
September 12, 2022
Shasqi announced today it has opened the Phase 2 of their Phase 1/2a clinical study to further assess SQ3370 in anthracycline- naïve patients
January 7, 2022
Founder and CEO, José M. Mejía Oneto, M.D., Ph.D., will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 10 a.m. EST.
November 11, 2021
Shasqi announced a Series B funding round of $50 million driven by a syndicate of private investors, including Juan Jaen, Ph.D., President of Arcus Biosciences and Bill Rieflin, Executive Chairman of the Board at NGM Biopharmaceuticals.
November 04, 2021
Shasqi announced upcoming presentations at both SITC and CTOS, sharing updated data from its Phase 1 clinical study of SQ3370 in patients with advanced solid tumors, and nonclinical data on SQ3370 in combination with cancer immunotherapies.
September 16, 2021
Shasqi presented interim data from its Phase 1 clinical study of SQ3370 in advanced sarcomas and other solid tumors, as well as additional non-clinical data at the European Society for Medical Oncology, (ESMO) Congress, being held virtually on September 16-21, 2021.
April 27, 2021
Shasqi announced today that it has been awarded a $2 million Direct-to-Phase-2 Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). These non-dilutive funds will support immune biomarker analysis of patient samples from Shasqi’s Phase 1 clinical trial of lead candidate SQ3370 as well as manufacturing process development.
April 10, 2021
Shasqi will present preclinical data and the Phase 1 clinical trial design for its lead clinical candidate, SQ3370, at the upcoming virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
February 10, 2021
Shasqi announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.
January 27, 2021
Shasqi announced today the publication of two preclinical studies highlighting the potential of the company’s click chemistry-based approach to the development of treatments for a range of solid cancers.
January 07, 2021
Shasqi, a clinical stage biotechnology company whose mission is to enable patients to beat cancer without poisoning their bodies, announced today that Founder & Chief Executive Officer José M. Mejía Oneto, MD, PhD, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday January 13th at 2:00pm Eastern Time.
November 20, 2020
Shasqi presents two posters at The Connective Tissue Oncology Society (CTOS) 25th Anniversary Annual Meeting showcasing their lead candidate SQ3370.
November 12, 2020
Shasqi presents two posters on their lead candidate, SQ3370, at The Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting.
October 14, 2020
First Patients Dosed in Phase 1 Clinical Study of SQ3370 for Advanced Solid Tumor Malignancies. Shasqi is First Y-Combinator Biotech Company to Reach First-in-Human Clinical Studies.
SAN FRANCISCO, CA. – October 14, 2020 – Shasqi announced today the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370.
October 08, 2020
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform, announced today that the Company has appointed Wayne Saville, M.D., as Chief Medical Officer, and Juan Jaen, Ph.D., President & Co-founder of Arcus Biosciences, as a member of the Shasqi board of directors.
June 22, 2020
Shasqi, a leader in chemistry based locally-activated cancer drugs, presented data showing that the company’s lead candidate SQ3370 produced robust anti-tumor responses both at the target site and at distal lesions in a preclinical cancer model. The study, titled “SQ3370, a Local Activation Therapy of Cytotoxic Agents, Produces Sustained Responses in Target and Distal Lesions via Immune Activation,” was presented in a poster with audio at the American Association for Cancer Research Virtual Annual Meeting II.
October 31, 2019
Shasqi, Inc., a privately held company focused on improving the localized delivery of cancer drugs to tumors, today announced the completion of a $10 million Series A financing. The proceeds of the financing are being used to complete GMP manufacturing for the company’s lead drug candidate and to support a Phase 1 human trial, expected to commence in Q2 2020.
July 20, 2016
Scientists at Shasqi, Inc. and SUNY University at Albany have published research demonstrating a way to target drugs to specific areas of the body, enabling greater efficacy and fewer side-effects. The method, called local drug activation, uses activating agents in an injected polymer gel to concentrate and activate prodrug versions of a drug, such as a chemotherapeutic, directly at a desired location, limiting the drug's action to that specific site. The researchers recently published their findings online in ACS Central Science, the open-access flagship journal of the American Chemical Society.